Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations
Combination therapy with neratinib and palbociclib demonstrated a favorable safety profile and clinical benefit rate in patients with HER-driven alterations. Pharmacokinetic analysis revealed a CYP3A4-mediated drug-drug interaction, leading to reduced clearance and increased plasma exposure of both agents, underscoring the importance of considering metabolic interactions in future clinical development.
Authors
- Aung Naing (ORCID: https://orcid.org/0000-0002-4803-8513)
- Michael Murphy (ORCID: https://orcid.org/0000-0001-6722-7080)
- P T Soliman
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Siqing Fu (ORCID: https://orcid.org/0000-0002-1933-0419)
- David Ramírez
- Hai T. Tran (ORCID: https://orcid.org/0000-0003-4065-9355)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- F. Meric-Bernstam
- Anil K. Sood (ORCID: https://orcid.org/0000-0002-5415-9901)
- Jae Yun Lim
- Chieh Tseng
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105895
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00